February 24th, 2015
We are honored that for the second consecutive year FORTUNE Magazine ranked Johnson & Johnson and its Janssen Pharmaceutical Companies #1 in the Pharmaceuticals category on its annual World’s Most Admired Companies list. It is a reflection of the hard work, passion and dedication of our Janssen team, and a testament to our commitment to improve people’s lives around the world.
At Janssen, what matters most is a healthy outcome for every patient and this cannot be achieved by simply making incremental improvements to healthcare. We must continue to be bold, collaborative and innovative. Here are some examples of progress we’ve made over the past year:
- Our efforts to combat Ebola, in partnership with Bavarian Nordic and consortia of leading global research institutions and NGOs reflect our commitment to global public health;
- Agreements with organizations like Stop TB Partnership’s Global Drug Facility are helping to expand access to our medicines;
- Through the Johnson & Johnson Innovation Centers‒JLabs, we are expanding our reach, identifying the best science and partners in life science hot spots around the globe; and
- New recently-launched research platforms — the Janssen Prevention Center, the Disease Interception Accelerator, and the Janssen Human Microbiome Institute — focus in three areas of transformational medical innovation that are expected to change the global healthcare landscape.